Investing in Longevity (Nils Regge, Apollo Health Ventures)
Listen now
Description
Joining Chris on the podcast today is Nils Regge, Co-founder and Managing Director of Apollo Health Ventures.  As a social entrepreneur, company creator, and biotech expert, Nils built Apollo Health Ventures in 2016 to help health tech companies develop methods to prevent and reverse the aging process and extend the healthy human life span.   At Apollo, Nils makes use of his dealmaking skills, business knowledge, and prior experience growing startups to help boost the success of biotech and health companies.  As the general public becomes increasingly interested in longevity and medical advancements continue to take place at rapid rates, Apollo is a leader in funding and fueling efforts to ensure  healthier  and longer human lifespans. At the moment,  things are looking up as there is a lot of excitement  in the industry - however, Regge finds it important to temper that enthusiasm with the right kind of skepticism.   In a field in which any new advancement is seemingly revolutionary, it’s crucial to stay grounded.  The Finer Details of This Episode:  Incentive and organizational structuresFiltering for good ideasApollo’s portfolio of companies Fusing European and American techniques for company buildingThe heightened need for fundingBringing drugs into the clinic Quotes:  “If you have something that makes you live 10 years, 20 years, longer, healthier, I think it's the biggest market ever.” “We do company creation, but we also invest in outside companies.” “Because we are in this for the long run, we want to make investors money, we want to show the investors that this is a good place to invest or a good space to invest. And then ultimately, we want to be able to raise more money from other bigger institutional investors.” “You want to create an incentive structure and organizational structure that encourages the right kind of skepticism…you almost want to avoid a certain kind of optimism early on.” “But because of the excitement in the field, and kind of what I think of as the ‘True Believer' phenomenon, I think we are vulnerable to a little bit of hype. And I think that it's a very good idea to bring that down to earth and say, ‘Okay, that's a good idea. Let us figure out the best way to see if it's gonna fail, and do that first.’” “So first of all, it's about getting a drug to the market, that's the most important thing, and making sure it's safe and that it's working.” “There's great science here in Europe, right? So I mean, the universities are great, the people are smart. They're just not as entrepreneurial as they are in the US, per se.” Links:  Email questions, comments, and feedback to [email protected] Translating Aging on Twitter: @bioagepodcast BIOAGE Labs Website BIOAGELabs.com BIOAGE Labs Twitter @bioagelabs BIOAGE Labs LinkedIn Apollo Health Ventures Homepage: https://www.apollo.vc  Nils Regge on LinkedIn: nils-regge-62ab7a28 
More Episodes
Dr. Daisy Robinton, co-founder and CEO of Oviva Therapeutics, discusses the company's innovative approach to improving women's healthspan by targeting the biology of ovarian aging. Motivated by her personal experiences and the realization that female physiology is underserved by research and...
Published 04/03/24
Published 04/03/24
Dr. Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, discusses the company's innovative work using gene therapies to treat age-related diseases in dogs and humans. In his conversation with host Chris Patil, he explains his recent groundbreaking study showing that partial cellular...
Published 03/20/24